Business
Defence Therapeutics Announces Formation of Scientific Advisory Board to Guide Advancement of Accum-Enhanced Antibody Drug Conjugate Programs
Montreal, Quebec--(Newsfile Corp. - December 4, 2025) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTCQB: DTCFF) ("Defence" or the "Company"), a biotechnology company advancing a proprietary intracellular delivery platform that enables more potent, safer, and more effective antibody-based and radiotherapeutic treatments, is pleased to announce the formation of its inaugural Scientific Advisory Board ("SAB"), composed of Rob Leanna, Danny Chui, and Brendan Hussey.Defence's Accum®-Antibody..
About this update from Defence Therapeutics Inc Class A
[{"type":"text","content":"Montreal, Quebec--(Newsfile Corp. - December 4, 2025) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTCQB: DTCFF) ("Defence" or the "Company"), a biotechnology company advancing a proprietary intracellular delivery platform that enables more potent, safer, and more effective antibody-based and radiotherapeutic treatments, is pleased to announce the formation of its inaugural Scientific Advisory Board ("SAB"), composed of Rob Leanna, Danny Chui, and Brendan Hussey.","length":513,"tagName":"p"},{"type":"text","content":"Defence's Accum®-Antibody drug conjugate ("ADC") program has reached laboratory validations, demonstrating a significant increase in intracellular accumulation and improved efficacy for Accum®-enhanced ADCs. As the Company continues to advance Accum®-enabled ADC programs, the Scientific Advisory Board will play a key role in providing scientific, technical, and strategic guidance, shaping program direction and scientific priorities.","length":450,"tagName":"p"},{"type":"text","content":""Our Scientific Advisory Board brings together deep expertise across antibody-based therapeutics, intracellular delivery, translational biology, biomanufacturing, and biotech development," said Maxime Parisotto, PhD, MBA, Chief Scientific Officer of Defence Therapeutics. "Rob, Danny, and Brendan each contribute complementary perspectives that will strengthen our scientific and development strategy as we advance Accum®-powered therapeutics."","length":464,"tagName":"p"},{"type":"text","content":"The backgrounds of the Scientific Advisory Board members reflect the breadth of expertise required to advance Accum® from preclinical development toward translation and scale.","length":175,"tagName":"p"},{"type":"text","content":"Rob Leanna is a seasoned pharmaceutical industry veteran with extensive experience in antibody-drug conjugates (ADC) and drug-linker chemistry. Over his decades-long career with AbbVie Inc. he has led development, scale-up, and regulatory strategy for complex biologics and conjugated therapeutics. Now an independent consultant, he advises biotech companies on ADC CMC and development strategy. Rob will play a key role in guiding Defence's CMC approach as Accum®-enhanced ADC programs progress toward clinical development.","length":528,"...